|
|
ASH 2011: Dr. Berdeja - Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
Jesus G. Berdeja, MD
Sarah Cannon Research Institute
Nashville, Tennessee, USA
|
|
|
back
button next to the volume control in the
lower right hand corner.
print
related articles